Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of trabectedin + olaparib versus physician's choice in DNA repair-deficient advanced solid tumors
2017-001755-31Phase 2Completed
- Sponsor
- Heidelberg University
- Start
- Mar 2018
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trabectedin and olaparib in Nonhematologic neoplasms (2 arms), sponsored by Heidelberg University. Primary endpoint: Disease control rate at week 16. Started Mar 2018; status: completed.
02
Drugs
trabectedinolaparib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2017-001755-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001755-31.